A Republican bill with 2 Republican cosponsors · See all 2 cosponsors
Last activity — Read twice and referred to the Committee on Finance.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, known as the "USTRx Act," aims to combat international trade practices where high-income countries use price controls on pharmaceuticals. It seeks to stop these countries from unfairly exploiting United States innovation by deviating from market-based policies. To achieve this, the legislation creates the position of Chief Pharmaceutical Trade Negotiator. This official will advocate for United States pharmaceutical manufacturers and consumers. Additionally, the bill requires an annual report to review the pharmaceutical trade practices of high-income countries. Finally, it establishes a process for the United States to respond to adverse trade actions taken by these countries.
Yes· 3 of 9
- Scored +5
Does this make patent and copyright rules fairer?
The bill seeks to protect the value of U.S. pharmaceutical innovation against foreign exploitation.
- Scored +5
Does this give people more protection from unfair business practices?
The bill seeks to protect U.S. consumers by ensuring continued access to innovative pharmaceutical treatments.
- Scored +5
Does this make health care easier to get in general?
The bill aims to safeguard access to new, innovative life-saving treatments for U.S. patients.
The opposite
- Scored -3
Does this lower the price of prescription medicines?
By opposing foreign price controls, the bill may indirectly support maintaining higher market-based prices for innovation.
- Scored -2
Does this strengthen ties with allied countries?
The bill may create tension with high-income allies through trade disputes and retaliatory actions.
Who it would affect, and how
Potential Positive Impacts for People
-
Ensuring Access to Treatments: The bill states that combating foreign price controls is necessary to safeguard access to life-saving treatments for United States patients and consumers (Section 2(a)(2) and Section 2(b)(4)).
-
Protecting Innovation Incentives: By addressing policies that mandate artificially low drug prices, the bill seeks to prevent the reduction of global incentives to invest in the development of new medicines (Section 2(a)(2) and Section 2(b)(2)).
-
Reducing Financial Burden on Americans: The legislation aims to stop the unfair shift of development costs to the United States, where United States patients and taxpayers currently rely on financing global pharmaceutical innovation (Section 2(b)(3)).
-
Stronger Advocacy for Manufacturers and Consumers: The creation of a Chief Pharmaceutical Trade Negotiator provides a dedicated official to conduct negotiations, enforce trade agreements, and advocate for United States pharmaceutical manufacturers and consumers (Section 3).
Potential Negative Impacts for People
- Threats to Access via Price Controls: The bill's findings suggest that current foreign price controls could threaten to restrict access to new treatments and cures for United States patients and consumers (Section 2(a)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Education And Technology
- Does this make patent and copyright rules fairer? — The bill seeks to protect the value of U.S. pharmaceutical innovation against foreign exploitation. Does this put more money into scientific research? — The bill aims to sustain the economic drivers of pharmaceutical research and development.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill seeks to protect U.S. consumers by ensuring continued access to innovative pharmaceutical treatments.
- Governance And Ideology
- Does this give the federal government more power? — The bill expands the authority of the U.S. Trade Representative to take action against foreign practices. Does this make what the government does easier for the public to see? — The bill requires annual public reporting on foreign pharmaceutical trade practices.
- Healthcare
- Does this make health care easier to get in general? — The bill aims to safeguard access to new, innovative life-saving treatments for U.S. patients. Does this put more money into medical research? — The bill protects the economic incentives necessary to drive pharmaceutical research and development. Does this lower the price of prescription medicines? — By opposing foreign price controls, the bill may indirectly support maintaining higher market-based prices for innovation.
- Demographic And Interest Groups
- Would business owners be better off under this? — The bill provides significant advocacy and protection for pharmaceutical manufacturers.
- National Security And Foreign Policy
- Does this make trade with other countries easier? — The bill advocates for fairer market access for U.S. pharmaceutical exports. Does this strengthen ties with allied countries? — The bill may create tension with high-income allies through trade disputes and retaliatory actions.
- 8/5/2026
- Read twice and referred to the Committee on Finance.
- 2 Cosponsors added.
- Introduced in Senate
Ted BuddRepublican · North Carolina
David McCormickRepublican · Pennsylvania